Conventional type 1 dendritic cells (cDC1) in cancer immunity.

Humans Dendritic Cells / pathology Neoplasms / therapy Immunotherapy CD8-Positive T-Lymphocytes / pathology

Journal

Biology direct
ISSN: 1745-6150
Titre abrégé: Biol Direct
Pays: England
ID NLM: 101258412

Informations de publication

Date de publication:
01 11 2023
Historique:
received: 09 10 2023
accepted: 23 10 2023
medline: 2 11 2023
pubmed: 1 11 2023
entrez: 1 11 2023
Statut: epublish

Résumé

Cancer immunotherapy, alone or in combination with conventional therapies, has revolutionized the landscape of antineoplastic treatments, with dendritic cells (DC) emerging as key orchestrators of anti-tumor immune responses. Among the distinct DC subsets, conventional type 1 dendritic cells (cDC1) have gained prominence due to their unique ability to cross-present antigens and activate cytotoxic T lymphocytes. This review summarizes the distinctive characteristics of cDC1, their pivotal role in anticancer immunity, and the potential applications of cDC1-based strategies in immunotherapy.

Identifiants

DOI: 10.1186/s13062-023-00430-5 PMID: 37907944 PMC: PMC10619282
pubmed: 37907944
doi: 10.1186/s13062-023-00430-5
pii: 10.1186/s13062-023-00430-5
pmc: PMC10619282
doi:

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

71

Informations de copyright

© 2023. The Author(s).

Références

Nat Med. 2007 Jan;13(1):54-61
pubmed: 17187072
Cancers (Basel). 2019 Apr 03;11(4):
pubmed: 30987228
Cancer Discov. 2021 Feb;11(2):408-423
pubmed: 33046534
Immunity. 2013 Apr 18;38(4):729-41
pubmed: 23562161
Front Immunol. 2020 Jun 19;11:1267
pubmed: 32655564
Sci Immunol. 2022 Apr;7(70):eabm9409
pubmed: 35363544
Cancer Cell. 2017 May 8;31(5):711-723.e4
pubmed: 28486109
Cancer Res. 2021 Sep 1;81(17):4514-4528
pubmed: 34266895
Cancer Res. 2022 Dec 2;82(23):4373-4385
pubmed: 36130020
Oncoimmunology. 2016 Jun 09;5(7):e1177692
pubmed: 27622029
Nat Med. 2014 Nov;20(11):1301-9
pubmed: 25344738
Oncoimmunology. 2021 Nov 2;10(1):1996686
pubmed: 34745770
Cancer Immunol Immunother. 2023 Sep;72(9):3013-3027
pubmed: 37294342
Science. 2015 Nov 20;350(6263):972-8
pubmed: 26516201
Immunity. 2018 Jun 19;48(6):1077-1080
pubmed: 29924973
Science. 2017 Jun 9;356(6342):
pubmed: 28473638
Cell Death Differ. 2023 May;30(5):1097-1154
pubmed: 37100955
Nat Med. 2018 Aug;24(8):1178-1191
pubmed: 29942093
Science. 2011 Dec 16;334(6062):1573-7
pubmed: 22174255
Annu Rev Immunol. 2013;31:563-604
pubmed: 23516985
Nat Med. 2019 Jun;25(6):920-928
pubmed: 31086347
Cells. 2022 Nov 18;11(22):
pubmed: 36429101
Blood. 2007 Jun 1;109(11):4839-45
pubmed: 17299090
Eur J Cancer. 2020 Aug;135:173-182
pubmed: 32590296
EClinicalMedicine. 2022 May 27;49:101430
pubmed: 35747193
Biochem Pharmacol. 2018 Jul;153:12-23
pubmed: 29438676
Science. 2017 Apr 21;356(6335):
pubmed: 28428369
J Immunother Cancer. 2023 Jul;11(7):
pubmed: 37419511
PLoS One. 2013 Apr 23;8(4):e62621
pubmed: 23626840
Blood. 2016 Dec 29;128(26):3113-3124
pubmed: 27802968
Cell Death Dis. 2010 Dec 02;1:e104
pubmed: 21368877
J Immunother Cancer. 2021 Mar;9(3):
pubmed: 33737342
Cancer Discov. 2023 Nov 1;13(11):2448-2469
pubmed: 37623817
J Hepatol. 2022 Aug;77(2):467-478
pubmed: 35367532
Nat Commun. 2021 Apr 14;12(1):2237
pubmed: 33854047
Nat Rev Immunol. 2009 May;9(5):353-63
pubmed: 19365408
Cancer Cell. 2023 Jun 12;41(6):1014-1016
pubmed: 37207656
Nat Med. 2023 Aug;29(8):2087-2098
pubmed: 37563240
Annu Rev Immunol. 2016 May 20;34:93-119
pubmed: 26735697
Clin Transl Immunology. 2021 Jul 14;10(7):e1305
pubmed: 34277006
Oncoimmunology. 2023 Jun 27;12(1):2227510
pubmed: 37389102
Oncoimmunology. 2018 Nov 22;8(2):e1546068
pubmed: 30713806
PLoS One. 2021 Nov 30;16(11):e0260636
pubmed: 34847189
Science. 2008 Nov 14;322(5904):1097-100
pubmed: 19008445
Nat Immunol. 2018 Aug;19(8):885-897
pubmed: 30013147
Cancer Cell. 2014 Nov 10;26(5):638-52
pubmed: 25446897
Oncoimmunology. 2018 Feb 15;7(6):e1431086
pubmed: 29872558
Cell Death Differ. 2023 Oct 16;:
pubmed: 37845384
J Immunol. 1994 Jun 1;152(11):5398-403
pubmed: 8189059
Nat Immunol. 2018 Jul;19(7):711-722
pubmed: 29925996
Nat Med. 2023 Jun;29(6):1310-1312
pubmed: 37193799
Mol Ther. 2018 Jun 6;26(6):1471-1481
pubmed: 29628306
Nat Immunol. 2019 Jul;20(7):852-864
pubmed: 31213723
Nat Med. 2007 Sep;13(9):1050-9
pubmed: 17704786
Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3029-34
pubmed: 18272486
Trends Cancer. 2018 Nov;4(11):784-792
pubmed: 30352680
Lancet Oncol. 2020 May;21(5):645-654
pubmed: 32224306
Cell. 2023 Apr 13;186(8):1652-1669
pubmed: 37059068
Cancer Cell. 2018 Jan 8;33(1):60-74.e6
pubmed: 29316433
Oncoimmunology. 2016 May 13;5(8):e1185583
pubmed: 27622059
Oncoimmunology. 2022 Jun 24;11(1):2093518
pubmed: 35769948
Int J Mol Sci. 2019 Feb 22;20(4):
pubmed: 30813267
J Immunother Cancer. 2021 May;9(5):
pubmed: 33980589
Oncogene. 2016 Nov 17;35(46):5931-5941
pubmed: 27086930
J Immunother Cancer. 2019 Apr 8;7(1):100
pubmed: 30961656
Sci Transl Med. 2021 May 19;13(594):
pubmed: 34011627
Methods Cell Biol. 2022;172:135-143
pubmed: 36064220
Nature. 2020 Apr;580(7802):257-262
pubmed: 32269339
Blood. 2012 Jun 21;119(25):6052-62
pubmed: 22442345
Cancer Cell. 2014 Dec 8;26(6):938
pubmed: 28898680
J Transl Med. 2023 Mar 2;21(1):162
pubmed: 36864446
Cell. 2021 Jul 22;184(15):4016-4031.e22
pubmed: 34081922
Cancer Cell. 2014 Nov 10;26(5):623-37
pubmed: 25446896
STAR Protoc. 2021 Aug 12;2(3):100732
pubmed: 34430908
Immunity. 2016 Apr 19;44(4):924-38
pubmed: 27096321
Sci Transl Med. 2012 Jul 18;4(143):143ra99
pubmed: 22814852
Nature. 2002 Jul 11;418(6894):191-5
pubmed: 12110890
Nat Commun. 2018 Mar 28;9(1):1250
pubmed: 29593283
Cancer Discov. 2016 Jan;6(1):71-9
pubmed: 26493961
Nat Med. 2022 Dec;28(12):2573-2583
pubmed: 36482103
J Immunother Cancer. 2021 Jan;9(1):
pubmed: 33408092
J Immunol. 2011 Nov 1;187(9):4411-5
pubmed: 21948982
J Immunother Cancer. 2022 Sep;10(9):
pubmed: 36162919
Cancer Res. 2018 Dec 1;78(23):6643-6654
pubmed: 30297531
Immunity. 2021 Jun 8;54(6):1154-1167.e7
pubmed: 33979578
Immunology. 2022 Jan;165(1):99-109
pubmed: 34431087
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
J Immunother Cancer. 2020 Apr;8(1):
pubmed: 32273347
Nat Immunol. 2020 Oct;21(10):1160-1171
pubmed: 32747819
Cancer Cell. 2023 Aug 14;41(8):1498-1515.e10
pubmed: 37451271
Cell. 2018 Feb 22;172(5):1022-1037.e14
pubmed: 29429633
Cancer Cell. 2014 Nov 10;26(5):591-3
pubmed: 25517740
J Clin Invest. 2008 Jun;118(6):1991-2001
pubmed: 18523649

Auteurs

Peng Liu (P)

Centre de Recherche des Cordeliers, Equipe Labellisée par la Ligue Contre le Cancer, Université de Paris Cité, Inserm U1138, Institut Universitaire de France, Sorbonne Université, 75006, Paris, France.
Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, 94800, Villejuif, France.

Liwei Zhao (L)

Centre de Recherche des Cordeliers, Equipe Labellisée par la Ligue Contre le Cancer, Université de Paris Cité, Inserm U1138, Institut Universitaire de France, Sorbonne Université, 75006, Paris, France.
Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, 94800, Villejuif, France.

Guido Kroemer (G)

Centre de Recherche des Cordeliers, Equipe Labellisée par la Ligue Contre le Cancer, Université de Paris Cité, Inserm U1138, Institut Universitaire de France, Sorbonne Université, 75006, Paris, France. kroemer@orange.fr.
Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, 94800, Villejuif, France. kroemer@orange.fr.
Department of Biology, Institut du Cancer Paris CARPEM, Hôpital Européen Georges Pompidou, AP-HP, 75015, Paris, France. kroemer@orange.fr.

Oliver Kepp (O)

Centre de Recherche des Cordeliers, Equipe Labellisée par la Ligue Contre le Cancer, Université de Paris Cité, Inserm U1138, Institut Universitaire de France, Sorbonne Université, 75006, Paris, France. captain.olsen@gmail.com.
Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, 94800, Villejuif, France. captain.olsen@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Conventional type 1 dendritic cells (cDC1) in...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Système phagocytaire mononucléé › Cellules dendritiques › Conventional type 1 dendritic cells (cDC1) in...
questionsmedicales.fr › Tumeurs › Conventional type 1 dendritic cells (cDC1) in...
questionsmedicales.fr › Thérapeutique › Biothérapie › Immunothérapie › Conventional type 1 dendritic cells (cDC1) in...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD8+ › Conventional type 1 dendritic cells (cDC1) in...